Pneumococcal Vaccines
Conditions
Brief summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Detailed description
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to PCV20 in adults aged 50 to 64 years of age.
Interventions
BIOLOGICAL24 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
BIOLOGICAL20 valent pneumococcal conjugate vaccine
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Sponsors
Vaxcyte, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Triple (Participant, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study. * Able and willing to complete the informed consent process. * Available for clinical follow-up through the last study visit at 6 months after the study vaccination. * In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator. * Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant. * Willing to have blood samples collected, stored indefinitely, and used for research purposes. * Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process. * Negative pregnancy test (urine and serum) for women of childbearing potential.
Exclusion criteria
* Previous pneumococcal disease (either confirmed or by self-reporting). * Previous receipt of a licensed or investigational pneumococcal vaccine. * Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study. * Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29. * Physical examination indicating any clinically significant medical condition. * Body Temperature \> 38.0°C (\> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled). * Seropositive to HIV, HCV, or HBsAg. * History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis. * Female who is breast-feeding or planning to become pregnant during study participation. * Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. * Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine. * Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent. * Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study. * Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study. * Receiving immunosuppressive therapy. * History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | 7 days after vaccination | Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group |
| Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | 7 days after vaccination | Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain |
| Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 1 month after vaccination | Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination. |
| Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | 6 months after vaccination | Percentage of participants with SAEs and NOCIs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 month after vaccination | Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24 |
| VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 1 month after vaccination | Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24 |
| Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | 1 month after vaccination | Shifts from Normal at Baseline to Abnormal on Day 29 in Clinical Chemistry Parameters Occurring in \>5% of Subjects Aged 50 to 64 Years |
Countries
United States
Participant flow
Recruitment details
First subject was enrolled 22-Feb-2022 and last subject randomized/vaccinated was 01-Jul-22. Study sites were medical clinics.
Pre-assignment details
In Phase 1, 95 participants were screened; 21 did not meet inclusion/exclusion criteria, 4 withdrew consent, and 6 discontinued for other reason. Five of Phase 1 screen failures were rescreened and enrolled in Phase 2. An additional 1001 participants were screened (for a total of 1006); of these, 235 failed screening: 173 did not meet inclusion/exclusion criteria, 12 withdrew consent, and 50 failed for other reasons.
Participants by arm
| Arm | Count |
|---|---|
| VAX-24 Low Dose 18-49 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 1.1 mcg dose level.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 16 |
| VAX-24 Mid Dose 18-49 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 2.2 mcg dose level.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 16 |
| VAX-24 Mixed Dose 18-49 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 2.2 mcg/4.4 mcg dose levels.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 16 |
| PCV20 18-49 Yrs Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
20 valent pneumococcal conjugate vaccine: 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1 | 16 |
| VAX-24 Low Dose 50-64 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 1.1 mcg dose level.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 193 |
| VAX-24 Mid Dose 50-64 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 2.2 mcg dose level.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 192 |
| VAX-24 Mixed Dose 50-64 Yrs Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at 2.2 mcg/4.4 mcg dose levels.
24 valent pneumococcal conjugate vaccine: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1 | 192 |
| PCV20 50-64 Yrs Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
20 valent pneumococcal conjugate vaccine: 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1 | 194 |
| Total | 835 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Phase 1, Adults 18-49 Years of Age | Lost to Follow-up | 1 | 1 | 0 | 0 |
| Phase 1, Adults 18-49 Years of Age | Withdrawal by Subject | 0 | 0 | 0 | 1 |
| Phase 2, Adults 50-64 Years | Lost to Follow-up | 6 | 6 | 3 | 1 |
| Phase 2, Adults 50-64 Years | Unavailable for follow up | 1 | 0 | 0 | 1 |
| Phase 2, Adults 50-64 Years | Withdrawal by Subject | 0 | 0 | 2 | 0 |
Baseline characteristics
| Characteristic | VAX-24 Low Dose 18-49 Yrs | VAX-24 Mid Dose 18-49 Yrs | VAX-24 Mixed Dose 18-49 Yrs | PCV20 18-49 Yrs | VAX-24 Low Dose 50-64 Yrs | VAX-24 Mid Dose 50-64 Yrs | VAX-24 Mixed Dose 50-64 Yrs | PCV20 50-64 Yrs | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 39.5 Years | 34.0 Years | 39.0 Years | 37.0 Years | 57.0 Years | 57.0 Years | 57.0 Years | 57.0 Years | 57.0 Years |
| Body Mass Index (kg/m^2) Median, Q1 - Q3 | 26.99 kg/m^2 | 31.09 kg/m^2 | 29.16 kg/m^2 | 26.91 kg/m^2 | 29.87 kg/m^2 | 30.65 kg/m^2 | 29.34 kg/m^2 | 29.06 kg/m^2 | 29.49 kg/m^2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 5 Participants | 2 Participants | 3 Participants | 22 Participants | 18 Participants | 22 Participants | 17 Participants | 93 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants | 10 Participants | 14 Participants | 13 Participants | 171 Participants | 172 Participants | 168 Participants | 177 Participants | 737 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 5 Participants |
| Height (cm) | 176.1 cm | 170.1 cm | 167.1 cm | 170.8 cm | 168.3 cm | 167.6 cm | 167.6 cm | 167.6 cm | 167.6 cm |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 2 Participants | 3 Participants | 8 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 7 Participants | 4 Participants | 10 Participants | 40 Participants | 32 Participants | 29 Participants | 29 Participants | 156 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 4 Participants | 3 Participants | 11 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants | 2 Participants | 1 Participants | 3 Participants | 10 Participants |
| Race (NIH/OMB) White | 10 Participants | 8 Participants | 12 Participants | 4 Participants | 145 Participants | 157 Participants | 156 Participants | 154 Participants | 646 Participants |
| Region of Enrollment United States | 16 participants | 16 participants | 16 participants | 16 participants | 193 participants | 192 participants | 192 participants | 194 participants | 835 participants |
| Sex: Female, Male Female | 7 Participants | 7 Participants | 8 Participants | 8 Participants | 110 Participants | 121 Participants | 134 Participants | 127 Participants | 522 Participants |
| Sex: Female, Male Male | 9 Participants | 9 Participants | 8 Participants | 8 Participants | 83 Participants | 71 Participants | 58 Participants | 67 Participants | 313 Participants |
| Weight (kg) | 80.85 kg | 92.10 kg | 90.50 kg | 78.07 kg | 87.82 kg | 86.72 kg | 83.10 kg | 82.83 kg | 84.81 kg |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 193 | 0 / 191 | 0 / 191 | 0 / 196 | 0 / 209 | 0 / 207 | 0 / 207 | 0 / 212 |
| other Total, other adverse events | 9 / 16 | 13 / 16 | 14 / 16 | 16 / 16 | 161 / 193 | 155 / 191 | 164 / 191 | 163 / 196 | 170 / 209 | 168 / 207 | 178 / 207 | 179 / 212 |
| serious Total, serious adverse events | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 2 / 193 | 3 / 191 | 1 / 191 | 4 / 196 | 2 / 209 | 3 / 207 | 1 / 207 | 4 / 212 |
Outcome results
Primary
Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI)
Percentage of participants with SAEs and NOCIs
Time frame: 6 months after vaccination
Population: Safety population, including all subjects in the exposed population who provided safety assessment data. Subject safety data were analyzed according to the vaccine regimen they received: 1 subject was randomized to VAX-24 2.2/4.4 mcg but received VAX-24 2.2 mcg, and 2 subjects were randomized to VAX-24 2.2 mcg but received PCV20.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 0 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 0 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 0 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 0 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 1.0 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 1.6 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 1.6 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 1.6 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0.5 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 3.1 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 2.6 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 2.0 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 1.4 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 1.0 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 1.4 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 1.4 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 0.5 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 2.9 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one SAE | 1.9 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Subjects with at least one NOCI | 2.4 percentage of participants |
Primary
Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group
Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group
Time frame: 7 days after vaccination
Population: Safety population, defined as all patients exposed to study vaccine. Subject safety data were analyzed according to the vaccine regimen they received: 1 subject was randomized to VAX-24 2.2/4.4 mcg but received VAX-24 2.2 mcg, and 2 subjects were randomized to VAX-24 2.2 mcg but received PCV20.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 6.3 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 56.3 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 18.8 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 56.3 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 75.0 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 81.3 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 6.3 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 12.5 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 81.3 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 81.3 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 18.8 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 25.0 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 93.8 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 18.8 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 81.3 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 25.0 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 71.0 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 8.8 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 6.7 percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 73.6 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 71.7 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 71.2 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 7.9 percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 7.9 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 8.9 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 77.5 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 77.0 percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 7.9 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 69.9 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 71.9 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 10.7 percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 8.7 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 6.7 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 9.6 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 69.9 percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 72.2 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 72.5 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 7.7 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 71.5 percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 8.2 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 77.3 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 9.7 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 77.8 percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 9.2 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Any solicited local AE; Overall, Any Grade | 73.6 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Erythema (redness) at injection site; Overall, Any Grade | 9.9 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Pain at injection site; Overall, Any Grade | 70.8 percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Edema (swelling) at injection site; Overall, Any Grade | 11.3 percentage of participants |
Primary
Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain
Time frame: 7 days after vaccination
Population: Safety population, which included all subjects in the Exposed Population who provided safety assessment data. Subject safety data were analyzed according to the vaccine regimen they received: 1 subject was randomized to VAX-24 2.2/4.4 mcg but received VAX-24 2.2 mcg, and 2 subjects were randomized to VAX-24 2.2 mcg but received PCV20.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 31.3 Percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 50.0 Percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 25.0 Percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 37.5 Percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 6.3 Percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 37.5 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 12.5 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 37.5 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 62.5 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 31.3 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 6.3 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 37.5 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 37.5 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 18.8 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 0.0 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 56.3 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 12.5 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 25.0 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 75.0 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 43.8 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 12.5 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 56.3 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 50.0 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 37.5 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.0 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 24.9 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 69.4 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 42.5 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 57.0 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.6 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 56.0 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 69.6 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 0.5 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 40.8 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 28.8 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 16.2 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 71.2 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 2.1 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 60.2 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.4 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 40.8 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 27.7 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 53.1 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 39.8 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 24.0 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.0 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.1 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 64.8 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 67.9 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 55.5 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 24.9 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.6 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 42.1 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.4 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 40.1 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 29.5 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.0 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 54.6 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 69.1 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 15.9 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 70.0 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 40.6 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.9 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.0 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 26.6 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 57.0 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fatigue | 40.6 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Muscle Pain | 53.3 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Any solicited systemic adverse event | 65.6 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Fever (oral temperature >= 100.4ºF) | 1.9 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Headache | 30.7 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Joint Pain | 25.5 Percentage of participants |
Primary
Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group
Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination.
Time frame: 1 month after vaccination
Population: Safety population, including all subjects in the Exposed Population who provided safety assessment data. Subject safety data were analyzed according to the vaccine regimen they received: 1 subject was randomized to VAX-24 2.2/4.4 mcg but received VAX-24 2.2 mcg, and 2 subjects were randomized to VAX-24 2.2 mcg but received PCV20.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 12.5 Percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 12.5 Percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 6.3 Percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 6.3 Percentage of participants |
| VAX-24 Low Dose 50-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 15.5 Percentage of participants |
| VAX-24 Mid Dose 50-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 11.5 Percentage of participants |
| VAX-24 Mixed Dose 50-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 13.1 Percentage of participants |
| PCV20 50-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 16.8 Percentage of participants |
| VAX24 Low Dose 18-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 15.3 Percentage of participants |
| VAX-24 Mid Dose 18-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 11.6 Percentage of participants |
| VAX-24 Mixed Dose 18-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 12.6 Percentage of participants |
| PCV20 18-64 Yrs | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | 16.0 Percentage of participants |
Secondary
Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values
Shifts from Normal at Baseline to Abnormal on Day 29 in Clinical Chemistry Parameters Occurring in \>5% of Subjects Aged 50 to 64 Years
Time frame: 1 month after vaccination
Population: Prespecified analysis population included all subjects age 50-64 in the Exposed Population who provided safety assessment data. Subject safety data were analyzed according to the vaccine regimen they received: 1 subject was randomized to VAX-24 2.2/4.4 mcg but received VAX-24 2.2 mcg, and 2 subjects were randomized to VAX-24 2.2 mcg but received PCV20.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Glucose: High | 7.2 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Cholesterol: High | 7.2 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Uric Acid: High | 8.1 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Triglycerides: High | 9.1 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Creatinine: High | 11.5 percentage of participants |
| VAX-24 Low Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Bicarbonate: Low | 14.4 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Cholesterol: High | 7.7 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Bicarbonate: Low | 18.4 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Triglycerides: High | 8.2 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Glucose: High | 3.9 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Creatinine: High | 11.1 percentage of participants |
| VAX-24 Mid Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Uric Acid: High | 7.2 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Bicarbonate: Low | 15.0 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Cholesterol: High | 8.7 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Glucose: High | 5.3 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Creatinine: High | 10.6 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Uric Acid: High | 2.9 percentage of participants |
| VAX-24 Mixed Dose 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Triglycerides: High | 9.7 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Uric Acid: High | 5.7 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Bicarbonate: Low | 11.8 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Cholesterol: High | 8.5 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Triglycerides: High | 10.8 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Creatinine: High | 8.5 percentage of participants |
| PCV20 18-49 Yrs | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Glucose: High | 7.1 percentage of participants |
Secondary
VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs)
Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after vaccination
Population: Prespecified Immunogenicity Evaluable Population included all subjects 50 to 64 years in the Exposed Population with no major protocol deviation impacting immunogenicity assessment, no prohibited medication or vaccine, and provided evaluable serum sample results for baseline and Day 29 within required time frames. Data were analyzed according to vaccine received: 1 subject randomized to VAX-24 2.2/4.4 mcg received VAX-24 2.2 mcg; 2 subjects randomized to VAX-24 2.2 mcg received PCV20.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 20B | 19.53 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 10A | 6.73 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9V | 3.93 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6B | 2.83 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 2 | 13.31 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9N | 7.98 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 8 | 8.94 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 7F | 4.97 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 22F | 4.13 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19F | 4.98 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19A | 7.35 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 3 | 0.41 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 1 | 2.85 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 18C | 6.66 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 17F | 9.57 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 4 | 1.79 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 33F | 12.20 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 15B | 10.67 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 14 | 8.62 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 5 | 2.13 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 23F | 4.60 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 12F | 1.73 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 11A | 5.62 mcg/mL |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6A | 3.92 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 14 | 10.47 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 1 | 4.65 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 2 | 16.37 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 3 | 0.53 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 4 | 2.52 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 5 | 2.42 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6A | 4.66 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6B | 3.78 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 7F | 6.29 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 8 | 8.79 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9N | 10.78 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9V | 5.12 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 10A | 7.90 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 11A | 5.76 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 12F | 2.13 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 15B | 14.09 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 17F | 10.51 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 18C | 8.50 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19A | 9.21 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19F | 8.92 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 20B | 24.90 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 22F | 5.45 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 23F | 5.90 mcg/mL |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 33F | 17.58 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 33F | 11.82 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 18C | 10.35 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 20B | 19.40 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 14 | 10.47 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 23F | 5.27 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19A | 11.50 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 5 | 1.78 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 2 | 18.73 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 4 | 1.83 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 7F | 8.82 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 22F | 3.81 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 15B | 11.59 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19F | 9.96 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 8 | 8.94 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 12F | 1.91 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6B | 4.43 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 11A | 4.87 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9N | 7.91 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 1 | 4.01 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 17F | 9.89 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 10A | 6.58 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9V | 7.15 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 3 | 0.79 mcg/mL |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6A | 4.38 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19A | 8.84 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 10A | 9.38 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 5 | 3.70 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 33F | 9.73 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 11A | 3.72 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 12F | 1.15 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 4 | 2.02 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 14 | 8.17 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 22F | 7.32 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 15B | 14.81 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 3 | 0.48 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 17F | 0.46 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 18C | 6.67 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 2 | 1.02 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 20B | 4.06 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 23F | 5.18 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 7F | 4.74 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6B | 2.44 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 8 | 7.30 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 19F | 4.34 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9N | 2.52 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 6A | 4.62 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 1 | 4.39 mcg/mL |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | 9V | 2.94 mcg/mL |
Secondary
VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs)
Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after vaccination
Population: Prespecified Immunogenicity Evaluable Population included all subjects 50 to 64 years in the Exposed Population with no major protocol deviation impacting immunogenicity assessment, no prohibited medication or vaccine, and provided evaluable serum sample results for baseline and Day 29 within required time frames. Data were analyzed according to vaccine received: 1 subject randomized to VAX-24 2.2/4.4 mcg received VAX-24 2.2 mcg; 2 subjects randomized to VAX-24 2.2 mcg received PCV20.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 8205.88 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 3506.32 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 491.01 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1229.24 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 4156.84 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 3318.45 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 190.08 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 2596.46 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 3252.03 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 2344.26 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 6243.38 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 8217.87 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 319.33 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 1928.24 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 2384.28 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 2735.58 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 1000.62 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 2317.55 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 3398.89 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 4351.67 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 11672.18 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1371.45 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1550.61 Titer |
| VAX-24 Low Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1117.61 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 2307.24 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 5653.21 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 2347.67 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 8545.04 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 7164.92 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 3604.41 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 1368.00 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 17099.25 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1698.18 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 4646.32 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 4359.57 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 317.62 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 2483.57 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 9753.78 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 407.13 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 3028.18 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 5800.54 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1076.79 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1717.83 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 4282.68 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 3242.54 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 2301.19 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 3435.80 Titer |
| VAX-24 Mid Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 546.38 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 228.09 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 4103.02 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1064.03 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 4867.77 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 11856.15 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 3218.37 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1549.29 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 2290.15 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 857.41 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 366.50 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 4107.89 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1326.49 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 4843.18 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 2668.87 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 6211.37 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 9066.94 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 2535.37 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 5962.25 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 7809.21 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 3757.52 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 497.72 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 1822.43 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 2453.82 Titer |
| VAX-24 Mixed Dose 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 5366.49 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 33F | 11030.39 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 1 | 358.18 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 2 | 62.40 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 3 | 343.29 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 4 | 1414.77 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 5 | 691.28 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6A | 3932.31 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 6B | 3783.96 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 7F | 3975.12 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 8 | 2267.98 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9N | 1636.07 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 9V | 1733.44 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 10A | 5533.20 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 11A | 1038.01 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 12F | 1914.42 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 14 | 3634.47 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 15B | 3137.65 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 17F | 666.74 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 18C | 1963.65 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19A | 4813.63 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 19F | 1419.27 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 20B | 140.23 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 22F | 7631.74 Titer |
| PCV20 18-49 Yrs | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | 23F | 962.52 Titer |